FDA Grants rare paediatric disease designation for elamipretide for Barth Syndrome

Elamipretide is a mitochondrial permeability transition pore inhibitor currently under investigation in phase III trials. US FDA rare paediatric disease designation is granted for conditions that affect fewer than 200,000 people in the US.

Source:

Biospace Inc.